| Literature DB >> 29562524 |
Harald Hampel1,2,3,4, Nicola Toschi5,6,7, Claudio Babiloni8,9, Filippo Baldacci1,2,3,4,10, Keith L Black11, Arun L W Bokde12, René S Bun1,2,3,4, Francesco Cacciola13, Enrica Cavedo1,2,3,4,14, Patrizia A Chiesa1,2,3,4, Olivier Colliot15, Cristina-Maria Coman1,2,3,4, Bruno Dubois16, Andrea Duggento5, Stanley Durrleman17, Maria-Teresa Ferretti18,19, Nathalie George20, Remy Genthon16, Marie-Odile Habert21,22, Karl Herholz23,24, Yosef Koronyo11, Maya Koronyo-Hamaoui11,25, Foudil Lamari26, Todd Langevin27, Stéphane Lehéricy28,29, Jean Lorenceau30, Christian Neri31, Robert Nisticò32, Francis Nyasse-Messene16, Craig Ritchie33, Simone Rossi34,35, Emiliano Santarnecchi34,36, Olaf Sporns37,38, Steven R Verdooner39, Andrea Vergallo1,2,3,4, Nicolas Villain2,3,4, Erfan Younesi40, Francesco Garaci5,41, Simone Lista1,2,3,4.
Abstract
The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular, and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression. This translational research path is paralleled by an "omics"-based, hypothesis-free, exploratory research pathway, which will collect multimodal data from progressing asymptomatic, preclinical, and clinical neurodegenerative disease (ND) populations, within the wide continuous biological and clinical spectrum of ND, applying high-throughput and high-content technologies combined with powerful computational and statistical modeling tools, aimed at identifying novel dysfunctional systems and predictive marker signatures associated with ND. The goals are to identify common biological denominators or differentiating classifiers across the continuum of ND during detectable stages of pathophysiological progression, characterize systems-based intermediate endophenotypes, validate multi-modal novel diagnostic systems biomarkers, and advance clinical intervention trial designs by utilizing systems-based intermediate endophenotypes and candidate surrogate markers. Achieving these goals is key to the ultimate development of early and effective individualized treatment of ND, such as Alzheimer's disease. The Alzheimer Precision Medicine Initiative (APMI) and cohort program (APMI-CP), as well as the Paris based core of the Sorbonne University Clinical Research Group "Alzheimer Precision Medicine" (GRC-APM) were recently launched to facilitate the passageway from conventional clinical diagnostic and drug development toward breakthrough innovation based on the investigation of the comprehensive biological nature of aging individuals. The APMI movement is gaining momentum to systematically apply both systems neurophysiology and systems biology in exploratory translational neuroscience research on ND.Entities:
Keywords: Alzheimer’s disease; biomarkers; integrative disease modeling; pathophysiology; precision medicine; precision neurology; systems biology; systems neurophysiology; systems pharmacology; systems theory
Mesh:
Year: 2018 PMID: 29562524 PMCID: PMC6008221 DOI: 10.3233/JAD-179932
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472